Abstract
AimTo compare outcome between patients treated using a modified treat-and-extend (mT&E) protocol and patients treated using a conventional T&E protocol.MethodsA retrospective cohort study of two groups of treatment-naïve neovascular age-related macular degeneration patients within a single centre were evaluated. One group treated using the conventional T&E protocol, with visual acuity, dilated fundus examination (DFE) and optical coherence tomography (OCT) performed at each visit. The second group treated using the mT&E protocol in which visual acuity and DFE were performed only every three visits. The main outcome measures were time spent per clinical visit, visual and anatomical outcomes measured for 36 months.ResultsThe T&E and mT&E groups included 135 eyes in 116 patients and 119 eyes in 94 patients, respectively, with similar baseline characteristics. At 36 months, the number of injections administered (7.9±2.9 vs 8.1±2.3 injections, respectively; p=0.55), the percentage of eyes that gained ≥15 Early Treatment for Diabetic Retinopathy Study (ETDRS) letters (23% vs 25.2%, respectively; p=0.39) and the percentage of eyes that lost ≥15 ETDRS letters (21.5% vs 17.7%; p=0.43, respectively) were similar between the T&E and mT&E groups. However, waiting and contact time were reduced during the OCT-only visits compared with the full visits, with an average of 41 min saved per patient encounter.ConclusionsBoth protocols yielded similar visual and anatomical outcomes. However, the mT&E protocol reduced the number of full visits, with considerably less time spent at the clinic.
Funder
Israel Science Foundation
Reference27 articles.
1. Five-Year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials;Maguire;Ophthalmology,2016
2. Ranibizumab for Neovascular Age-Related Macular Degeneration
3. Long-Term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles;Vofo;Br J Ophthalmol,2022
4. 2018 update on intravitreal injections: Euretina expert consensus recommendations;Grzybowski;Ophthalmologica,2018
5. The Royal College of Ophthalmologists . The way forward. options to help meet demand for the current and future care of patients with eye disease. age-related macular degeneration and diabetic retinopathy. London The Royal College of Ophthalmologists; 2015. https://www.rcophth.ac.uk/wp-content/uploads/2015/10/RCOphthThe-Way-Forward-AMD-300117.pdf [Accessed 1 Sep 2021].